Skip directly to content

Access to Hepatitis C Treatment Through State AIDS Drug Assistance Programs (ADAPs)

Addthis

By Tracy Swan

May 31, 2007

The Henry J. Kaiser Family Foundation and the National Association of State and Territorial AIDS Directors (NASTAD) released the 2007 National ADAP Monitoring Project Annual Report on April 10th, 2007.

Access to hepatitis C treatment is crucial for HIV/HCV coinfected people. Although hepatitis C can be treated, HCV-associated end-stage liver disease has become a leading cause of death among HIV-positive people in the US.

Although funding shortfalls and increasing need mean that the majority of ADAPs are currently unable to provide pegylated interferon and ribavirin, some are still covering HCV treatment and/or adjunctive therapies used to manage side effects (see table of State ADAP Coverage below). Some State ADAPs offer hepatitis A (HAV) and hepatitis B (HBV) vaccines, which are recommended for people with HIV and hepatitis C who are susceptible to these viruses.

If your State ADAP does not cover hepatitis C treatment, you may be able to obtain it through patient assistance programs sponsored by Roche and Schering.

  • Roche Patient Assistance Foundation: 1-877-75ROCHE (877-757-6243)
  • Schering Commitment to Care (1-800-521-7157)
  • Direct link to Schering's Commitment to Care Application (accessed May 21 2007): www.schering-plough.com/pdf/commitapp.pdf

 

State ADAP Coverage: Hepatitis A (HAV) & Hepatitis B (HBV) Vaccines, Hepatitis C Treatment, Growth Factors, & Selective Serotonin Reuptake Inhibitors (SSRIs) as of May 2007

State

IFN (PEG, Standard, Consensus)

RBV

SSRIs/
Other*

Epoetin-
Alfa

Filgrastim

HAV & HBV Vaccine

Waiting List/ Other Cost Containment

ALABAMA

 

 

 

X

 

 

Capped enrollment

ALASKA

 

 

 

 

 

X

 

ARIZONA

PEG-IFN

X

X

X

X

X

 

ARKANSAS

 

 

 

 

 

 

 

CALIFORNIA

Standard IFN

X

X

X

X

X

 

COLORADO

 

 

 

 

 

 

 

CONNECTICUT

PEG-IFN

X

X

 

X

X

 

DELAWARE

PEG-IFN

X

X

X

X

 

 

DISTRICT OF COLUMBIA

Standard IFN

X

X

X

 

 

 

FLORIDA

 

 

 

X

X

X

Lowered income eligibility

GEORGIA

 

 

 

X

 

 

 

HAWAII

 

 

X

X

X

 

 

IDAHO

 

 

 

 

 

 

Cost containment anticipated before 3/31/08

ILLINOIS

Standard IFN

 

 

 

 

 

 

INDIANA

 

 

X

 

 

 

Capped enrollment

IOWA

 

 

 

 

 

 

 

KANSAS

 

 

 

 

 

 

 

KENTUCKY

 

 

 

 

 

X

Cost containment anticipated before 3/31/08

LOUISIANA

 

 

 

 

 

 

 

MAINE

 

 

 

 

 

 

 

MARYLAND

PEG-IFN, Standard IFN

X

X

 

X

 

 

MASSACHUSETTS

All FDA-approved drugs are covered**

MICHIGAN

PEG-IFN, Standard IFN

X

X

X

X

X

Formulary management

MINNESOTA

 

 

X

 

 

 

 

MISSISSIPPI

PEG-IFN

X

X

 

 

 

Lowered medical eligibility

MISSOURI

 

 

X

 

 

X

 

MONTANA

 

 

X

X

X

 

Waiting list

NEBRASKA

 

 

X

X

X

 

 

NEVADA

 

 

X

X

 

 

 

NEW HAMPSHIRE

 

X

X

X

 

 

Cost containment anticipated before 3/31/08

NEW JERSEY

All FDA-approved drugs are covered**

NEW MEXICO

 

 

X

X

 

X

 

NEW YORK

PEG-IFN

X

X

X

X

X

 

NORTH CAROLINA

 

 

X

 

 

 

 

NORTH DAKOTA

 

 

X

 

 

X

 

OHIO

 

 

X

 

X

 

 

OKLAHOMA

 

 

 

 

 

 

 

OREGON

 

 

 

X

X

 

 

PENNSYLVANIA

PEG-IFN

X

 

X

X

X

 

PUERTO RICO

PEG-IFN, Standard IFN

X

X

X

X

 

Waiting List

RHODE ISLAND

PEG-IFN, Standard IFN

X

X

 

 

 

Lowered income eligibility; additional cost containment anticipated by 3/31/08

SOUTH CAROLINA

 

 

X

 

 

X

Waiting List; reduced formulary; capped enrollment

SOUTH DAKOTA

 

 

X

 

 

X

 

TENNESSEE

PEG-IFN

X

X

 

X

 

 

TEXAS

 

 

 

 

 

 

 

U.S. VIRGIN ISLANDS

 

 

 

 

 

 

Client cost sharing; additional cost containment anticipated by 3/31/08

UTAH

 

 

 

 

 

 

 

VERMONT

 

 

X

 

X

X

 

VIRGINIA

PEG-IFN

X

 

X

 

X

 

WASHINGTON

PEG-IFN, Standard IFN

X

X

X

 

X

 

WEST VIRGINIA

 

 

 

 

 

 

 

WISCONSIN

PEG-IFN

X

X (Elavil only)

 

 

X

 

WYOMING

 

X

 

 

 

X

 

 


* May include anti-anxiety agents, anti-depressants, anti-psychotics, mood stabilizers, and other psychiatric medications.

**With certain exclusions.

Sources:

  1. Henry J. Kaiser Family Foundation, National Alliance of State and Territorial AIDS Directors (NASTAD). National ADAP Monitoring Project, Annual Report, April 2007. ADAP Formularies. Available on-line at: www.kff.org/hivaids/7619.cfm (accessed on May 9th, 2007).

  2. NASTAD. ADAP Watch. April 2007. Available on-line at: www.nastad.org/Publications/adapwatch.aspx (accessed on May 9th, 2007).

Thanks to Britten Ginsburg, Murray Penner, Beth Crutsinger-Perry and Chris Taylor at NASTAD.

Tracy Swan is TAG's Coinfection Project Director.